Such a vaccine could be used to treat bird flu in people, as concern grows about H5N1 cases spreading in dairy cows across the country, the U.S. Department of Health and Human Services (HHS) noted.
“We have successfully taken lessons learned during the COVID-19 pandemic and used them to better prepare for future public health crises. As part of that, we continue to develop new vaccines and other tools to help address influenza and bolster our pandemic response capabilities,” HHS Secretary Xavier Becerra said in a news release announcing the investment. “The Biden-Harris Administration won’t stop until we have everything we need to prepare for pandemics and other public health emergencies that impact the American public.”
Moderna already has a bird flu vaccine in early-stage testing that uses the same mRNA technology that allowed a rapid rollout of COVID vaccines, the Associated Press reported.
Some of the new HHS funds will go toward a late-stage trial next year if early results with Moderna’s mRNA-based flu vaccine are positive.
“The award made today is part of our longstanding commitment to strengthen our preparedness for pandemic influenza,” Dawn O’Connell, assistant secretary for preparedness and response, said in the HHS news release. “Adding this technology to our pandemic flu toolkit enhances our ability to be nimble and quick against the circulating strains and their potential variants.”
The vaccine development could also quickly target another form of influenza if a threat other than the H5N1 form of bird flu emerges, HHS officials stressed.
The award was made through the Biomedical Advanced Research and Development Authority (BARDA), a program that focuses on medical treatments for potential pandemics.
The H5N1 virus was detected earlier this year in dairy cows and has spread to more than 135 herds in 12 states and has infected three people to date, all with mild cases.
In a bit of good news about bird flu, the U.S. Food and Drug Administration released results of a preliminary study last week that found flash pasteurization kills virtually all bird flu virus in milk.

Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
